| Literature DB >> 34043588 |
Sylvain Carras1,2,3, Dimitri Chartoire1,2,3, Sylvain Mareschal1,2,3, Maël Heiblig1,2,3,4, Antoine Marçais5, Rémy Robinot1,2,3, Mirjam Urb1,2,3, Roxane M Pommier6, Edith Julia1,2,3, Amel Chebel1,2,3, Aurélie Verney1,2,3, Charlotte Bertheau7, Emilie Bardel1,2,3, Caroline Fezelot1,2,3, Lucien Courtois1,2,3, Camille Lours1,2,3, Alyssa Bouska8, Sunandini Sharma8, Christine Lefebvre9,10, Jean-Pierre Rouault1,2,3, David Sibon11, Anthony Ferrari6, Javeed Iqbal8, Laurence de Leval12, Philippe Gaulard13,14, Alexandra Traverse-Glehen1,2,3,7, Pierre Sujobert1,2,3,15, Mathieu Blery16, Gilles Salles1,2,3,4, Thierry Walzer5, Emmanuel Bachy1,2,3,4, Laurent Genestier1,2,3.
Abstract
Peripheral T cell lymphomas (PTCLs) represent a significant unmet medical need with dismal clinical outcomes. The T cell receptor (TCR) is emerging as a key driver of T lymphocyte transformation. However, the role of chronic TCR activation in lymphomagenesis and in lymphoma cell survival is still poorly understood. Using a mouse model, we report that chronic TCR stimulation drove T cell lymphomagenesis, whereas TCR signaling did not contribute to PTCL survival. The combination of kinome, transcriptome, and epigenome analyses of mouse PTCLs revealed a NK cell-like reprogramming of PTCL cells with expression of NK receptors (NKRs) and downstream signaling molecules such as Tyrobp and SYK. Activating NKRs were functional in PTCLs and dependent on SYK activity. In vivo blockade of NKR signaling prolonged mouse survival, demonstrating the addiction of PTCLs to NKRs and downstream SYK/mTOR activity for their survival. We studied a large collection of human primary samples and identified several PTCLs recapitulating the phenotype described in this model by their expression of SYK and the NKR, suggesting a similar mechanism of lymphomagenesis and establishing a rationale for clinical studies targeting such molecules.Entities:
Keywords: Hematology; Immunology; Lymphomas; T cell receptor; T cells
Mesh:
Substances:
Year: 2021 PMID: 34043588 PMCID: PMC8245185 DOI: 10.1172/JCI139675
Source DB: PubMed Journal: J Clin Invest ISSN: 0021-9738 Impact factor: 14.808